PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com
Clinical Trials
Related News

Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.

Phase 3
Completed
Conditions
Anxiety Neuroses
First Posted Date
2005-09-08
Last Posted Date
2006-07-14
Lead Sponsor
Pfizer
Target Recruit Count
511
Registration Number
NCT00150449
Locations

Pfizer Investigational Site

Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan

Phase 3
Completed
Conditions
Infections, Nosocomial
First Posted Date
2005-09-08
Last Posted Date
2011-05-10
Lead Sponsor
Pfizer
Target Recruit Count
24
Registration Number
NCT00150332
Locations
🇯🇵

Pfizer Investigational Site, Okayama, Japan

Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Phase 3
Completed
Conditions
Seizure Disorder, Partial
First Posted Date
2005-09-08
Last Posted Date
2015-03-05
Lead Sponsor
Pfizer
Target Recruit Count
337
Registration Number
NCT00150293
Locations

Pfizer Investigational Site

Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients

Phase 3
Completed
Conditions
Possible Fungal Infection
Interventions
Drug: voriconazole (Vfend)
First Posted Date
2005-09-08
Last Posted Date
2012-01-19
Lead Sponsor
Pfizer
Target Recruit Count
147
Registration Number
NCT00150345
Locations
🇩🇪

Pfizer Investigational Site, Wuerzburg, Germany

A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension

Phase 3
Completed
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
First Posted Date
2005-09-08
Last Posted Date
2008-11-05
Lead Sponsor
Pfizer
Target Recruit Count
976
Registration Number
NCT00150267
Locations
🇬🇧

Pfizer Investigational Site, London, United Kingdom

Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose

Phase 3
Completed
Conditions
Diabetes Mellitus
First Posted Date
2005-09-08
Last Posted Date
2008-10-31
Lead Sponsor
Pfizer
Target Recruit Count
626
Registration Number
NCT00150410
Locations
🇲🇽

Pfizer Investigational Site, Mexico Df, Mexico

An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend

Phase 1
Terminated
Conditions
Kidney Failure
First Posted Date
2005-09-08
Last Posted Date
2008-09-29
Lead Sponsor
Pfizer
Target Recruit Count
1
Registration Number
NCT00150319
Locations
🇺🇸

Pfizer Investigational Site, Austin, Texas, United States

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

First Posted Date
2005-09-07
Last Posted Date
2013-10-30
Lead Sponsor
Pfizer
Target Recruit Count
282
Registration Number
NCT00147537
Locations
🇪🇸

Pfizer Investigational Site, Sevilla, Spain

Non-Comparative Study To Evaluate Changes In FMD After Quinapril Therapy In Hypertensive Women

Phase 4
Completed
Conditions
Menopause
Hypertension
First Posted Date
2005-09-07
Last Posted Date
2007-04-30
Lead Sponsor
Pfizer
Target Recruit Count
70
Registration Number
NCT00147524
Locations
🇭🇺

Pfizer Investigational Site, Szombathely, Hungary

Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.

Phase 2
Completed
Conditions
Alcoholism
First Posted Date
2005-09-07
Last Posted Date
2012-10-02
Lead Sponsor
Pfizer
Target Recruit Count
88
Registration Number
NCT00147576
Locations
🇺🇸

Pfizer Investigational Site, San Antonio, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy